ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-OR51

Effect of Finerenone on CKD Outcomes in Type 2 Diabetes

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical


  • Bakris, George L., University of Chicago Medicine, Chicago, Illinois, United States
  • Agarwal, Rajiv, Richard L. Roudebush VA Medical Center and Indiana University, Indianapolis, Indiana, United States
  • Anker, Stefan D., German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany
  • Pitt, Bertram, University of Michigan School of Medicine, Ann Arbor, Michigan, United States
  • Ruilope, Luis M., Institute of Research imas12, Madrid, Spain
  • Rossing, Peter, Steno Diabetes Center Copenhagen, Gentofte, Denmark
  • Kolkhof, Peter, Bayer AG, Wuppertal, Germany
  • Nowack, Christina, Bayer AG, Wuppertal, Germany
  • Schloemer, Patrick, Bayer AG, Berlin, Germany
  • Joseph, Amer, Bayer AG, Berlin, Germany
  • Filippatos, Gerasimos, National and Kapodistrian University of Athens, Athens, Greece

Group or Team Name

  • on behalf of the FIDELIO-DKD Investigators

Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) remain at risk of CKD progression despite guideline-directed therapies. Mineralocorticoid receptor (MR) overactivation may drive CKD progression through inflammatory and fibrotic processes. Finerenone, a novel, nonsteroidal MR antagonist, reduces albuminuria independent of hemodynamic effects. We assessed the long-term efficacy and safety of finerenone in slowing CKD progression in patients with CKD and T2D.


This global, phase 3, double-blind study randomized 5734 patients from 48 countries (1:1) to oral finerenone or placebo. Patients with T2D, urine albumin-to-creatinine ratio 30–5000 mg/g and estimated glomerular filtration rate (eGFR) 25–<75 mL/min/1.73 m2, treated with optimized renin–angiotensin system blockade, were included. The primary outcome was time to kidney failure, sustained eGFR decline ≥40% from baseline or renal death. The key secondary outcome was time to cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke or heart failure hospitalization. (NCT02540993)


Mean patient age was 65.6 years; 70.2% were male. At baseline, mean eGFR was 44.3 mL/min/1.73 m2 and median UACR 852 mg/g. The primary outcome occurred in 504/2833 (17.8%) and 600/2841 (21.1%) patients treated with finerenone and placebo, respectively (hazard ratio [HR]=0.82; 95% confidence interval [CI] 0.73–0.93; p=0.0014). The prespecified secondary outcome was also reduced with finerenone (13.0%) vs placebo (14.8%; HR=0.86; 95% CI 0.75–0.99, p=0.0339). Overall treatment-emergent adverse events were balanced between groups. The incidence of hyperkalemia-related treatment discontinuation was higher with finerenone than placebo (2.3% and 0.9%, respectively).


Finerenone significantly reduced kidney and CV outcomes in patients with T2D and advanced CKD and was well tolerated. While the primary adverse event was hyperkalemia, it only necessitated treatment discontinuation in 2.3% of patients compared to 0.9% in placebo. These data support the use of finerenone to slow CKD progression and reduce CV risk in patients with CKD and T2D.


  • Commercial Support